Elanco Strengthens Board of Directors with Addition of Stacey Ma
Elanco Animal Health (NYSE: ELAN) has appointed Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma, currently Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, brings extensive experience in biopharmaceutical development and manufacturing. She previously held leadership positions at Sana Biotechnology and Genentech/Roche. Dr. Ma was recognized as one of the 'Top 20 Women Leaders in Biopharma R&D' by Endpoints News in 2020 and is a Fellow of the American Institute for Medical and Biological Engineering. Her expertise will support Elanco's Innovation, Portfolio and Productivity strategy and development of next-generation pipeline products.
Elanco Animal Health (NYSE: ELAN) ha nominato la Dr.ssa Stacey Ma nel suo Consiglio di Amministrazione, con effetto immediato. La Dr.ssa Ma, attualmente Vicepresidente Esecutivo dello Sviluppo Farmaceutico e della Produzione presso Gilead Sciences, porta con sé una vasta esperienza nello sviluppo e nella produzione biopharmaceutica. In precedenza ha ricoperto ruoli di leadership presso Sana Biotechnology e Genentech/Roche. La Dr.ssa Ma è stata riconosciuta come una delle 'Top 20 Women Leaders in Biopharma R&D' da Endpoints News nel 2020 ed è una Fellow dell'American Institute for Medical and Biological Engineering. La sua expertise supporterà la strategia e lo sviluppo di Innovazione, Portafoglio e Produttività di Elanco, nonché lo sviluppo di prodotti della pipeline di nuova generazione.
Elanco Animal Health (NYSE: ELAN) ha nombrado a la Dra. Stacey Ma en su Junta Directiva, con efecto inmediato. La Dra. Ma, que actualmente es Vicepresidenta Ejecutiva de Desarrollo y Fabricación Farmacéutica en Gilead Sciences, aporta una amplia experiencia en el desarrollo y la fabricación biofarmacéutica. Anteriormente, ocupó puestos de liderazgo en Sana Biotechnology y Genentech/Roche. La Dra. Ma fue reconocida como una de las 'Top 20 Women Leaders in Biopharma R&D' por Endpoints News en 2020 y es Fellow del American Institute for Medical and Biological Engineering. Su experiencia apoyará la estrategia de Innovación, Cartera y Productividad de Elanco y el desarrollo de productos de próxima generación en su línea de productos.
Elanco Animal Health (NYSE: ELAN)은 Stacey Ma 박사를 이사회의 일원으로 즉시 임명했습니다. Ma 박사는 현재 Gilead Sciences의 제약 개발 및 제조 부사장으로 재직 중이며, 생물 제약 개발 및 제조에서 광범위한 경험을 가지고 있습니다. 그녀는 이전에 Sana Biotechnology와 Genentech/Roche에서 리더십 역할을 맡았습니다. Ma 박사는 2020년에 Endpoints News에서 'Top 20 Women Leaders in Biopharma R&D' 중 한 명으로 선정되었으며, 미국 의학 및 생물 공학 연구소의 펠로우입니다. 그녀의 전문성은 Elanco의 혁신, 포트폴리오 및 생산성 전략과 차세대 파이프라인 제품 개발을 지원할 것입니다.
Elanco Animal Health (NYSE: ELAN) a nommé Dr. Stacey Ma à son Conseil d'Administration, avec effet immédiat. Dr. Ma, actuellement Vice-Présidente Exécutive du Développement et de la Fabrication Pharmaceutiques chez Gilead Sciences, apporte une vaste expérience dans le développement et la fabrication biopharmaceutiques. Elle a précédemment occupé des postes de direction chez Sana Biotechnology et Genentech/Roche. Dr. Ma a été reconnue comme l'une des 'Top 20 Women Leaders in Biopharma R&D' par Endpoints News en 2020 et elle est membre de l'American Institute for Medical and Biological Engineering. Son expertise soutiendra la stratégie d'Innovation, de Portefeuille et de Productivité d'Elanco ainsi que le développement de produits de pipeline de nouvelle génération.
Elanco Animal Health (NYSE: ELAN) hat Dr. Stacey Ma mit sofortiger Wirkung in seinen Vorstand berufen. Dr. Ma, die derzeit Executive Vice President für Pharmazeutische Entwicklung und Herstellung bei Gilead Sciences ist, bringt umfangreiche Erfahrung in der biopharmazeutischen Entwicklung und Herstellung mit. Zuvor hatte sie Führungspositionen bei Sana Biotechnology und Genentech/Roche inne. Dr. Ma wurde 2020 von Endpoints News als eine der 'Top 20 Women Leaders in Biopharma R&D' ausgezeichnet und ist Fellow des American Institute for Medical and Biological Engineering. Ihr Fachwissen wird die Innovations-, Portfolio- und Produktivitätsstrategie von Elanco und die Entwicklung von Produkten der nächsten Generation unterstützen.
- Strategic addition of expertise in biopharmaceutical development and manufacturing to support product innovation
- Strengthening of technical operations and CMC strategy capabilities at board level
- Addition of experienced leadership with proven track record in global pharmaceutical operations
- None.
Ma brings deep manufacturing and innovation expertise
"We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product development, Chemistry, Manufacturing and Controls (CMC) strategy, and technical operations, combined with her proven leadership in driving innovation will be a welcome addition in the board room."
Dr. Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., where she is responsible for product and portfolio strategy, technical development, supply chain, quality, CMC regulatory, and manufacturing operations for Gilead's small- and large-molecule pipeline. Prior to Gilead, she held leadership positions at Sana Biotechnology, Inc. and Genentech/Roche, including Global Head of Pharma Technical Innovation, Manufacturing, Science and Technology.
"I am honored to join the Elanco Board of Directors," said Dr. Ma. "I am passionate about innovation and technical excellence in life sciences and look forward to contributing to Elanco's mission of improving the health and wellbeing of animals."
Dr. Ma's impressive career also includes significant contributions to the broader scientific community. She has co-chaired multiple international scientific conferences, served as an Associate Director of the Board of CASSS, and is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). She was recognized as one of the "Top 20 Women Leaders in Biopharma R&D" by Endpoints News in 2020.
"Stacey's guidance will be highly valuable as Elanco's Innovation, Portfolio and Productivity (IPP) strategy comes to life with our significant blockbuster potential products transitioning from research and regulatory to manufacturing scale up," said Jeff Simmons, CEO at Elanco Animal Health. "Her drug development and CMC experience will also be beneficial as part of our Innovation, Science and Technology Committee as we develop our growing next generation pipeline to deliver a consistent flow of high-impact innovation."
Dr. Ma holds masters and doctorate degrees in chemical engineering from Yale University and a bachelor's in chemical engineering from the University of
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Kathryn Grissom, +1.317.273.9284, kathryn.grissom@elancoah.com
Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-strengthens-board-of-directors-with-addition-of-stacey-ma-302301818.html
SOURCE Elanco Animal Health
FAQ
Who is the new Board Director appointed to Elanco (ELAN)?
What is Dr. Stacey Ma's role at Gilead Sciences before joining Elanco's (ELAN) board?
What recognition has Elanco's (ELAN) new board member Dr. Stacey Ma received?
